ライフサイエンスコーパス: demethylating agent

1 pression was restored after treatment with a demethylating agent.

2 lines was reactivated after treatment with a demethylating agent.

3 R amplicons of the region, and exposure to a demethylating agent.

4 ll line MDA-MB-231, which was treated with a demethylating agent.

5 ous p16ink4a in response to treatment with a demethylating agent.

6 xpression, which could be reactivated with a demethylating agent.

7 ting this protein to develop therapeutic DNA demethylating agents.

8 2'-deoxy-5-azacytidine (DAC, decitabine) as demethylating agents.

9 and changes that occur after treatment with demethylating agents.

10 rtunity for treatment of SONFH patients with demethylating agents.

11 its expression is restored by treatment with demethylating agents.

12 gene, Ogg1, could be reversed by the use of demethylating agents.

13 RMS biopsies and could be reactivated by DNA-demethylating agents.

14 erapeutic options such as Syk inhibitors and demethylating agents.

15 al specimens and functionally verified using demethylating agents.

16 We have investigated whether the demethylating agent 2'-deoxy-5-azacytidine (DAC) can be

17 Treatment of A2780/cp70 with the demethylating agent 2-deoxy-5'-azacytidine induces resen

18 omoters of these genes; furthermore, the DNA demethylating agent 5 aza-2'deoxycytidine (5-Aza-dC) ant

19 Treatment of the latter with the demethylating agent 5'-aza-2' deoxycytidine leads to re-

20 emonstrated recently that treatment with the demethylating agent 5'-aza-2'-deoxycytidine (5-Aza-dC) s

21 d cell lines tested after treatment with the demethylating agent 5'-aza-2-deoxycytidine.

22 noma cells MAP2 expression is induced by the demethylating agent 5-aza-2'-cytidine, and MAP2 promoter

23 Treatment of these cells with demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC) in

24 In glioma cells, treatment with the DNA demethylating agent 5-aza-2'-deoxycytidine (5-Aza-dC) wa

25 Treatment of LNCaP(CS) and PC-3 with the demethylating agent 5-aza-2'-deoxycytidine (5-AZAdC) rea

26 Ns might be silenced by methylation, the DNA demethylating agent 5-aza-2'-deoxycytidine (5-AZAdC) was

27 c cancer cell lines after treatment with the demethylating agent 5-aza-2'-deoxycytidine (5Aza-dC) and

28 ot restored by heat shock, but rather by the demethylating agent 5-aza-2'-deoxycytidine (Aza-C).

29 Treatment of these cell lines with the demethylating agent 5-aza-2'-deoxycytidine (DAC) up-regu

30 he HER4-negative BT20 cell line with the DNA demethylating agent 5-aza-2'-deoxycytidine (DAC)-enhance

31 either alone or in combination with the DNA-demethylating agent 5-aza-2'-deoxycytidine (DAC).

32 Treatment of SUSM-1 cells with the demethylating agent 5-aza-2'-deoxycytidine and the histo

33 Treatment with the DNA demethylating agent 5-aza-2'-deoxycytidine and/or the hi

34 apitulated or enhanced by treatment with the demethylating agent 5-aza-2'-deoxycytidine as well as by

35 wild-type female mice with low doses of the demethylating agent 5-aza-2'-deoxycytidine decreased the

36 Treatment with the demethylating agent 5-aza-2'-deoxycytidine leads to re-e

37 CRBP1 mRNA, and in vitro treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivated C

38 th loss of expression and treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivated S

39 Melanoma cell lines treated with the demethylating agent 5-AZA-2'-deoxycytidine reexpressed I

40 ermore, treatment of melanoma cells with the demethylating agent 5-aza-2'-deoxycytidine reinduces Rap

41 The demethylating agent 5-aza-2'-deoxycytidine restored casp

42 Treatment of these cell lines with demethylating agent 5-aza-2'-deoxycytidine restored ER m

43 and UM-UC13), and exposure to the chromatin demethylating agent 5-aza-2'-deoxycytidine restored HSPA

44 Treatment with the demethylating agent 5-aza-2'-deoxycytidine restored LKB1

45 Treatment of SMCs with the demethylating agent 5-aza-2'-deoxycytidine restored MCT3

46 Exposure to the demethylating agent 5-aza-2'-deoxycytidine restored RASS

47 Treatment with the demethylating agent 5-aza-2'-deoxycytidine resulted in T

48 (4) Treating MCF-7 cells with a demethylating agent 5-Aza-2'-deoxycytidine specifically

49 Treatment with the demethylating agent 5-aza-2'-deoxycytidine was able to r

50 owever, demethylation at SIE-1, induced by a demethylating agent 5-aza-2'-deoxycytidine, reactivated

51 cription of PLCepsilon1a and PLCepsilon1b by demethylating agent 5-aza-2'-deoxycytidine, suggesting e

52 and E-cadherin expression are induced by the demethylating agent 5-aza-2'-deoxycytidine.

53 region was restored after treatment with the demethylating agent 5-Aza-2'-deoxycytidine.

54 ative ovarian and breast cancer cells with a demethylating agent 5-aza-2'-deoxycytidine.

55 ent of the differentiated cells with the DNA demethylating agent 5-aza-2'-deoxycytidine.

56 activated in HTB-19 after treatment with the demethylating agent 5-aza-2'-deoxycytidine.

57 l line was restored after treatment with the demethylating agent 5-aza-2'-deoxycytidine.

58 restored by treatment of the cells with the demethylating agent 5-aza-2'-deoxycytidine.

59 e was restored after cell treatment with the demethylating agent 5-aza-2'-deoxycytidine.

60 -type mouse fibroblasts treated with the DNA demethylating agent 5-aza-2'-deoxycytidine.

61 also expressed after treatment with the DNA demethylating agent 5-aza-2'-deoxycytidine.

62 upon continued exposure to AH or by the DNA demethylating agent 5-aza-2'-deoxycytidine.

63 f T-24 bladder cancer cell line with the DNA demethylating agent 5-aza-2'-deoxycytidine.

64 2 ESCC cell lines and was reactivated by the demethylating agent 5-aza-2'-deoxycytidine.

65 h was readily reversed by treatment with DNA-demethylating agent 5-aza-2'-deoxycytidine.

66 arcinogen-transformed HBECs treated with the demethylating agent 5-aza-2'deoxycytidine revealed miR-1

67 Furthermore, the DNA demethylating agent 5-aza-2-deoxycytidine failed to upre

68 Ha, CaSki, and HeLa cells and treatment with demethylating agent 5-aza-2-deoxycytidine restored DOC2B

69 DNA-demethylating agent 5-Aza-2dC significantly restored the

70 recapitulated by a co-treatment with the DNA-demethylating agent 5-Aza-C and retinoic acid across var

71 treatment of humanized NSG mice with the DNA-demethylating agent 5-aza-cytidine distinctly enhanced t

72 The DNA demethylating agent 5-aza-dC did not increase NAG-1 expr

73 Treatment of CypA-KD P19 cells with the DNA demethylating agent 5-aza-dC reversed the silencing of P

74 The demethylating agent 5-Aza-dC was used and demonstrated r

75 In response to the chemotherapeutic and DNA-demethylating agent 5-aza-deoxycytidine (5-aza-dC), tran

76 Treatment with demethylating agent 5-aza-deoxycytidine and/or histone d

77 om MCF-7 and HepG2 cells, treatment with the demethylating agent 5-azacytidine (10 microM for 6 days)

78 res or within 96 hours by treatment with the demethylating agent 5-azacytidine (5-Aza).

79 Treatment of COX-2-methylated cells with the demethylating agent 5-azacytidine had a modest effect on

80 broblasts to nanomolar concentrations of the demethylating agent 5-azacytidine increased basal expres

81 urthermore, in each case, treatment with the demethylating agent 5-azacytidine induced expression of

82 that co-culturing HCT-116 cells with the DNA demethylating agent 5-azacytidine reverses promoter meth

83 xpression was restored by treatment with the demethylating agent 5-azacytidine.

84 ession was restored after treatment with the demethylating agent 5-azacytidine.

85 l lines before and after the addition of the demethylating agent 5-azacytidine.

86 and could be reversed by treatment with the demethylating agent 5-azacytidine.

87 an inactive human X chromosome with the DNA demethylating agent 5-azadeoxycytidine (5aCdr), and we t

88 ion of the silenced allele by either the DNA demethylating agent 5-azadeoxycytidine or the SIRT1 inhi

89 However, treatment with the demethylating agent 5-azadeoxycytidine reactivated the s

90 ties) syndrome and in cells treated with the demethylating agent 5-azadeoxycytidine.

91 cancer cells by in vitro treatment with the demethylating agent 5-azadeoxycytidine.

92 Treatment with the DNA demethylating agent 5-deoxy-azacytidine does not increas

93 MOR expression could also be induced by a demethylating agent (5'-aza-2'-deoxycytidine) or histone

94 The treatment with demethylating agent (5'-aza-2'-deoxycytidine) restored E

95 ported by inducing p16 expression with a DNA demethylating agent (5-aza-2'-deoxycytidine) in a melano

96 ng growth factor beta (TGF-beta) cytokine, a demethylating agent (5-azacytidine), B cell receptor eng

97 ment of ER-negative breast cancer cells with demethylating agents [5-aza-2'-deoxycytidine (5-aza-dC)]

98 Following treatment with a demethylating agent, 5 of 11 renal cell carcinoma (RCC)

99 we examined the therapeutic potential of the demethylating agent, 5'-aza-2'-deoxycytidine.

100 and two human fibroblast cell strains to the demethylating agent, 5-aza-2'-deoxycytidine (5-Aza-CdR),

101 Furthermore, treatment with the demethylating agent, 5-Aza-2'-deoxycytidine (5-Aza-dC),

102 Treatment with a demethylating agent, 5-aza-2'-deoxycytidine (DAC), resto

103 Treatment of MDA-MB-231 cells with the demethylating agent, 5-aza-2'-deoxycytidine (deoxyC) led

104 he CHS response in mice treated with the DNA demethylating agent, 5-aza-2'-deoxycytidine, after UVB e

105 The treatment of AtT20 cells with the demethylating agent, 5-Aza-2'-deoxycytidine, induced the

106 Treatment with a demethylating agent, 5-aza-2'-deoxycytidine, restored PR

107 astric cancer cell lines, treatment with the demethylating agent, 5-aza-2'-deoxycytidine, resulted in

108 l expressed CDX1 mRNA; when treated with the demethylating agent, 5-aza-2'-deoxycytidine, these five

109 -dependent manner following treatment with a demethylating agent, 5-aza-2'-deoxycytidine, was shown.

110 l lines at basal line and reactivated by the demethylating agent, 5-aza-2'-deoxycytidine.

111 Importantly, treatment with the DNA demethylating agent, 5-azacytidine (5-aza), was signific

112 X chromosome that has been treated with the demethylating agent, 5-azacytidine (5aC).

113 Treatment of cNJ101 cells with a demethylating agent, 5-azacytidine, and a histone deacet

114 l re-expression of ER was achieved using the demethylating agent, 5-azacytidine, and the HDAC inhibit

115 as reversed by treatment of the cells with a demethylating agent, 5-deoxyazacytidine.

116 We examined the effects of 2 demethylating agents, 5-azacytidine and decitabine on gr

117 d when these cells were treated with the DNA demethylating agents, 5-azacytidine or 2-deoxy-5-azacyti

118 f the offspring because treatment with a DNA-demethylating agent alleviated exacerbation of allergic

119 The combination of a demethylating agent and adoptive transfer of P1A-specifi

120 Pure GuaUre-dR was found to be an effective demethylating agent and was able to induce 5azaC-dR type

121 ad- lines or hybrids by treatment with a DNA demethylating agent and/or a histone deacetylase inhibit

122 Treatment with a CpG demethylating agent and/or histone deacetylase inhibitor

123 tionale for sequential administration of DNA demethylating agents and HDAC inhibitors in cancer patie

124 derstanding the anti-tumor mechanisms of DNA-demethylating agents and highlight the MDA5/MAVS/IRF7 pa

125 eactivation of tumor suppressor genes by DNA-demethylating agents and histone deacetylase (HDAC) inhi

126 n cancer cells, but not normal cells, by DNA-demethylating agents and histone deacetylase inhibitors

127 if so, novel therapeutic strategies such as demethylating agents and probiotic adjuncts, particularl

128 at inhibition of G9A/GLP synergized with DNA demethylating agents and that SUV39H1 constitutes a pote

129 garding the advantage of aerosol delivery of demethylating agents and the concept of priming tumors f

130 We found that treatment with CpG demethylating agents and/or histone deacetylase inhibito

131 nografts were treated with decitabine, a DNA demethylating agent, and cytarabine, a frontline cytotox

132 DNA demethylating agents are approved for some blood maligna

133 Two demethylating agents are approved in myelodysplastic syn

134 Demethylating agents are the standard of care for patien

135 ntial use of Ras and Jak/Stat inhibitors and demethylating agents as therapeutic modality for human l

136 ol on Ddo expression, treatment with the DNA-demethylating agent, azacitidine, causes increased mRNA

137 SYBL1 were derepressed by treatment with the demethylating agent azadeoxycytidine.

138 Because demethylating agents can induce reexpression of silenced

139 lenic marginal zone lymphoma cell lines to a demethylating agent caused partial reversion of the High

140 Exposure to demethylating agents caused reexpression of estrogen rec

141 Treatment with 5-azacytidine, a demethylating agent, causes Th2 cells to reverse histone

142 Treatment of the K562 leukemia cells with demethylating agent combined with all-trans-retinoic aci

143 2 was achieved by treatment with 5-aza-dC, a demethylating agent, concomitant with the release of MBD

144 ound that the endothelial cells treated with demethylating agents could significantly increase the ex

145 Treatment of tumor-bearing mice with the demethylating agent DAC at a nontoxic dose induces MLH1

146 st (VDA) nor an HDAC inhibitor (HDACI) nor a demethylating agent (DAC) individually could optimally u

147 se) polymerase inhibitor talazoparib and the demethylating agent decitabine efficacious in Trp53/Bcor

148 The DNA-demethylating agent decitabine recovers FBXL7 expression

149 ddition, treatment with the FDA-approved DNA demethylating agent decitabine was sufficient to reactiv

150 and targeting DNMT1 with hydralazine, a safe demethylating agent, delays cyst growth in Pkd1 mutant k

151 Combining DNA-demethylating agents (DNA methyltransferase inhibitors [

152 However, the use of DNA-demethylating agents (e.g. 5-aza-2'-deoxycytidine (5aza-

153 tic lesions justifies efforts to develop DNA demethylating agents for therapeutic benefit.

154 treatment of a heterozygous cell line with a demethylating agent further increased the allelic expres

155 DNA-demethylating agents have shown clinical anti-tumor effi

156 By treating neoplastic LGLs with a demethylating agent, IL-6-mediated SOCS3 expression was

157 version of an adult cell by exposing it to a demethylating agent immediately followed by differentiat

158 malignancy and a basis for potential use of demethylating agents in conjunction with TSH-promoted ra

159 inding warrants strong consideration for DNA demethylating agents in future clinical trials for child

160 view, we discuss the clinical development of demethylating agents in hematology, with a focus on azac

161 The potential role of demethylating agents in the management of this patient p

162 leukemic LGL survival, and suggest a role of demethylating agents in the treatment of this disorder.

163 This study indicates that DNA demethylating agents increase IGF-II expression primaril

164 5), that express little ER-beta mRNA, with a demethylating agent increased levels of receptor express

165 Moreover, treatment with a demethylating agent increased Runx3 gene transcription,

166 hepatoma bearing rats with 5-azacytidine, a demethylating agent, induced basal as well as heavy meta

167 ed with 5-aza-2'-deoxycytidine (5-aza-dC), a demethylating agent, induced p16 expression, inhibited c

168 5-Azacytidine (5-Aza), a DNA demethylating agent, induces expression of cardiac-speci

169 ncer cell lines to 5-aza-2' deoxycytidine, a demethylating agent, induces the reexpression of AR RNA

170 hether a histone deacetylase inhibitor and a demethylating agent influence CCR7 and CXCR4 expression

171 Treatment of NES1-nonexpressing cells with a demethylating agent led to reexpression of NES1, suggest

172 y, exogenous ascorbic acid, a TET-activating demethylating agent, led to reversal of the above oncoge

173 ulmonary carcinogenesis and suggest that DNA demethylating agents may be useful for activating miR-48

174 our results demonstrate that treatment with demethylating agents may engender the reexpression and f

175 n and systemic treatment with 5-Aza or other demethylating agents may have significant therapeutic be

176 These demethylating agents may induce T-cell attraction and en

177 Demethylating agents may prove to be effective candidate

178 gene expression is induced by treatment with demethylating agents, may identify novel genes with tumo

179 st importantly, treatment of AI cells with a demethylating agent or histone deacetylase inhibitors re

180 Treatment of CCA cells with decitabine (demethylating agent) or butyrate (histone deacetylase in

181 Treatment of the latter cells with a demethylating agent partially restored TSHR expression.

182 Treatment of IDH mutant gliomaspheres with a demethylating agent partially restores insulator functio

183 with loss of expression and treatment with a demethylating agent-reactivated RASSF1A gene expression.

184 Ku-80 cells with 5-azacytidine, a potent DNA demethylating agent, rendered MT-I gene inducible by hea

185 Treatment with a DNA-demethylating agent restored BVES expression in CRC cell

186 addition, treatment of these leukemias with demethylating agents restored the C/EBPalpha-C/EBPgamma

187 sion; (2) treatment of L/L cell lines with a demethylating agent resulted in re-expression of SHP1 pr

188 o a combination of hypoxia, TGF-beta1, and a demethylating agent results in NK cells that express kil

189 In mice, demethylating agents reversed cyclophosphamide-induced b

190 eactivation by 5-aza-2'-deoxycytidine, a DNA demethylating agent, show that DNA methylation occurring

191 Studies show that demethylating agents strongly upregulate the expression

192 Novel demethylating agents such as antisense DNA methyl transf

193 ls caution against the indiscriminate use of demethylating agents, such as 5-aza-2'-deoxycytidine (5-

194 at were upregulated after treatment with DNA demethylating agents, such as Azacytidine and several na

195 ild-type fibroblasts were treated with a DNA-demethylating agent, suggesting that genomic hypomethyla

196 cytosine analog 5-azacytidine (5-AzaC) is a demethylating agent that is also known to induce mutagen

197 preceding 3 years, were taking cytotoxic or demethylating agents that might interfere with the test,

198 zone lymphoma and optimize therapy by using demethylating agents to reverse the high-methylation phe

199 In this study, we show that zebularine (a demethylating agent) treatment of cancer cells led to in

200 mmary, a histone deacetylase inhibitor and a demethylating agent up-regulated CCR7 and CXCR4 expressi

201 ne deacetylase inhibitor entinostat with the demethylating agent vidaza profoundly affected growth of

202 breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expressio

203 cell lines and inducing resensitizaton with demethylating agents, we aimed to identify consistent me

204 Furthermore, both demethylating agents were found to synergize with the FA

205 egulated in glioma cell lines treated with a demethylating agent, whereas the expression level of the

206 in mouse and hP4 in human) responded to DNA demethylating agents, whereas the expression of IGF-II f

207 Combining DNA-demethylating agents with compounds, such as DZNep, that

208 Rb cells and suggest that the combination of demethylating agents with DR-activating modalities, such

209 significantly abated by Zebularine, a potent demethylating agent, with a consequent increase in the h

210 and Jak/Stat inhibitors as well as with the demethylating agent zebularine induced a strong apoptoti

211 genetic regenerative therapy that combines a demethylating agent, zebularine, with retinoic acid, act